The type 2 diabetes market is undergoing a paradigm shift, as treatment diversifies and moves further upstream ahead of insulin. Large companies, worried about balancing the costs required to maximize such a potentially huge global market, are re-aligning to share risks of full-scale investment.
Nothing highlights the opportunity and challenges more than Bristol Myers Squibb Co.’s and AstraZeneca PLC’s joint plan, announced on...